Xenon Pharmaceuticals Stock Performance
| XENE Stock | USD 40.47 0.28 0.70% |
The firm maintains a market beta of 1.0, which attests to possible diversification benefits within a given portfolio. Xenon Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Xenon Pharmaceuticals is expected to follow. At this point, Xenon Pharmaceuticals has a negative expected return of -0.0237%. Please make sure to check out Xenon Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Xenon Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Xenon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Xenon Pharmaceuticals is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 57.2 M | |
| Free Cash Flow | -150.9 M |
Xenon |
Xenon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 4,171 in Xenon Pharmaceuticals on November 2, 2024 and sell it today you would lose (124.00) from holding Xenon Pharmaceuticals or give up 2.97% of portfolio value over 90 days. Xenon Pharmaceuticals is currently does not generate positive expected returns and assumes 2.3076% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Xenon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xenon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xenon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xenon Pharmaceuticals, and traders can use it to determine the average amount a Xenon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0103
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | XENE |
Estimated Market Risk
| 2.31 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Xenon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xenon Pharmaceuticals by adding Xenon Pharmaceuticals to a well-diversified portfolio.
Xenon Pharmaceuticals Fundamentals Growth
Xenon Stock prices reflect investors' perceptions of the future prospects and financial health of Xenon Pharmaceuticals, and Xenon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xenon Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.44 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 3.87 X | ||||
| Price To Sales | 181.44 X | ||||
| EBITDA | (210.51 M) | ||||
| Cash And Equivalents | 788.24 M | ||||
| Cash Per Share | 12.66 X | ||||
| Total Debt | 10.9 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 12.31 X | ||||
| Cash Flow From Operations | (145.33 M) | ||||
| Earnings Per Share | (2.81) X | ||||
| Total Asset | 964.8 M | ||||
| Retained Earnings | (665.14 M) | ||||
| Current Asset | 60.87 M | ||||
| Current Liabilities | 2.78 M | ||||
About Xenon Pharmaceuticals Performance
By analyzing Xenon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Xenon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xenon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xenon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.Things to note about Xenon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Xenon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xenon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xenon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Net Loss for the year was (182.39 M) with loss before overhead, payroll, taxes, and interest of (177.91 M). | |
| Xenon Pharmaceuticals currently holds about 788.24 M in cash with (145.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66. | |
| Over 100.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Xenon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xenon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Xenon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xenon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xenon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xenon Pharmaceuticals' stock. These opinions can provide insight into Xenon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |